Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
$3.38
-0.7%
$3.67
$2.68
$41.33
$11.44M2.2110,569 shs52,291 shs
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$9.83
+1.8%
$7.60
$3.91
$13.99
$664.72M1.67815,241 shs332,554 shs
Fluidigm Co. stock logo
FLDM
Fluidigm
$3.66
$2.67
$7.51
$283.76M1.14968,838 shs60,126 shs
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$0.45
-5.0%
$0.42
$0.28
$3.60
$20.76M1.523.15 million shs628,680 shs
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
$6.00
$3.50
$7.95
N/A0.99294,806 shs773,040 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
+3.03%+0.59%-7.61%+1.19%-90.06%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
+1.15%-8.35%+30.19%+93.59%+20.60%
Fluidigm Co. stock logo
FLDM
Fluidigm
0.00%0.00%0.00%0.00%0.00%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
+4.71%-4.96%+15.81%-0.82%-83.17%
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
1.3674 of 5 stars
3.13.00.00.00.00.00.6
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
2.0584 of 5 stars
3.53.00.00.01.11.70.0
Fluidigm Co. stock logo
FLDM
Fluidigm
N/AN/AN/AN/AN/AN/AN/AN/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
4.14 of 5 stars
3.34.00.04.50.81.70.6
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
2.25
Hold$7.00107.41% Upside
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
3.00
Buy$25.67161.00% Upside
Fluidigm Co. stock logo
FLDM
Fluidigm
0.00
N/AN/AN/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
2.50
Moderate Buy$3.00572.65% Upside
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest EYPT, HBIO, FLDM, HTGM, and BNGO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$28.00
5/29/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
5/16/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$30.00 ➝ $26.00
5/13/2025
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSpeculative Buy ➝ Speculative Buy$4.50 ➝ $3.00
5/8/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$33.00 ➝ $27.00
4/9/2025
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
4/9/2025
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Sector Weight
(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
$30.78M0.37N/AN/A$18.12 per share0.19
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$43.27M15.64N/AN/A$4.93 per share1.99
Fluidigm Co. stock logo
FLDM
Fluidigm
$130.58M0.00N/AN/A$1.24 per share0.00
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$94.14M0.21$0.10 per share4.65$1.45 per share0.31
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
$6.37M0.00N/AN/A$2.44 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
-$112.02M-$138.92N/AN/A-294.05%-125.75%-71.96%8/6/2025 (Estimated)
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$130.87M-$2.41N/AN/AN/A-261.91%-54.27%-41.75%8/6/2025 (Estimated)
Fluidigm Co. stock logo
FLDM
Fluidigm
-$59.24M-$0.78N/AN/AN/A-45.36%-40.15%-14.86%N/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
-$12.40M-$1.32N/AN/A-63.51%-4.96%-2.24%8/14/2025 (Estimated)
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
-$21.59MN/A0.00N/AN/A-324.25%45.52%8.93%N/A

Latest EYPT, HBIO, FLDM, HTGM, and BNGO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
-$3.49-$1.15+$2.34-$1.15$6.25 million$6.46 million
5/7/2025Q1 2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$0.65-$0.65N/A-$0.65$8.84 million$24.50 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
N/AN/AN/AN/AN/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/AN/AN/AN/AN/A
Fluidigm Co. stock logo
FLDM
Fluidigm
N/AN/AN/AN/AN/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
N/AN/AN/AN/AN/A
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
0.07
1.70
1.34
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/A
7.85
7.79
Fluidigm Co. stock logo
FLDM
Fluidigm
0.68
1.45
1.03
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
N/A
0.81
0.40
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
N/A
1.40
1.30

Institutional Ownership

CompanyInstitutional Ownership
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
11.35%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
99.41%
Fluidigm Co. stock logo
FLDM
Fluidigm
76.59%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
80.87%
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
19.27%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bionano Genomics, Inc. stock logo
BNGO
Bionano Genomics
3003.36 million3.33 millionOptionable
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
12068.81 million65.74 millionOptionable
Fluidigm Co. stock logo
FLDM
Fluidigm
61576.49 million74.27 millionOptionable
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
49044.21 million40.01 millionOptionable
HTG Molecular Diagnostics, Inc. stock logo
HTGM
HTG Molecular Diagnostics
842.21 million2.16 millionOptionable

Recent News About These Companies

Creating an Efficient Molecular Diagnostics Ecosystem
HTGMQ HTG Molecular Diagnostics, Inc.
HTG Molecular Diagnostics Inc HTGMQ
HTG Molecular Diagnostics Inc (HTGMQ)
Molecular Diagnostics Virtual Event Series 2016
Regulating Molecular Diagnostic Assays
Molecular Diagnostics Virtual Event Series 2017

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bionano Genomics stock logo

Bionano Genomics NASDAQ:BNGO

$3.38 -0.03 (-0.74%)
Closing price 03:55 PM Eastern
Extended Trading
$3.38 +0.00 (+0.15%)
As of 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Eyepoint Pharmaceuticals stock logo

Eyepoint Pharmaceuticals NASDAQ:EYPT

$9.83 +0.17 (+1.80%)
Closing price 02:34 PM Eastern
Extended Trading
$9.84 +0.00 (+0.01%)
As of 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Fluidigm stock logo

Fluidigm NASDAQ:FLDM

Fluidigm Corporation creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Fluidigm Corporation has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Harvard Bioscience stock logo

Harvard Bioscience NASDAQ:HBIO

$0.45 -0.02 (-5.01%)
Closing price 03:56 PM Eastern
Extended Trading
$0.44 0.00 (-0.45%)
As of 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

HTG Molecular Diagnostics stock logo

HTG Molecular Diagnostics NASDAQ:HTGM

HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. It serves the biopharmaceutical companies, academic research centres, and molecular testing laboratories. Its proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.